Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Santa Ana Bio

Request full access

A biotech company focused on leveraging deep cell profiling technologies to design precision biologics in the autoimmune space

Alameda, United StatesFounded 2021Biotech & Life Sciences

About Santa Ana Bio

Santa Ana Bio is a cutting-edge company specializing in precision immunology, focusing on developing drugs for autoimmune diseases. The company leverages advanced technologies like single-cell genomics and sophisticated data analytics to create targeted treatments. This approach allows them to design therapies that are highly specific to individual patient needs, potentially improving outcomes and reducing side effects.

Santa Ana Bio operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from various autoimmune conditions. Autoimmune diseases occur when the body's immune system mistakenly attacks its own tissues, leading to chronic and often debilitating symptoms. By focusing on precision immunology, Santa Ana Bio aims to offer more effective and personalized treatment options for these patients.

The company's business model revolves around drug development, from initial research and discovery to clinical trials and eventual commercialization. They generate revenue through a combination of funding rounds, partnerships with larger pharmaceutical companies, and eventually, the sale of their developed drugs. Recently, Santa Ana Bio successfully closed its Series A financing, which will provide the necessary capital to advance its drug development programs.

Santa Ana Bio is committed to fostering a diverse and inclusive work environment, recognizing that a variety of perspectives can drive innovation and success. This commitment to diversity is not just a corporate value but a strategic advantage in developing groundbreaking treatments.

In summary, Santa Ana Bio is a biotech startup focused on precision immunology for autoimmune diseases, using advanced genomics and analytics to develop targeted therapies. They serve patients with autoimmune conditions and operate within the pharmaceutical and biotechnology markets. Their revenue model includes funding rounds, partnerships, and drug sales.

Source: Dealroom company data

At a glance

Status
Operational
Employees
35
Open positions
None listed
Dealroom signal
64.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2024 $43M $172M Versant Ventures ↗
SERIES BOther financing Jun 2024 $125M $500M TPG · Andreessen Horowitz · RTW Investments · Access Biotechnology ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Santa Ana Bio website traffic

Latest recorded traffic for Santa Ana Bio is 2.7K monthly website visits, up 3.8% over the last three months. Santa Ana Bio's team grew 2.9% over the past year.

Latest monthly visits2.7K 3-month web change+3.8% 1-year team growth+2.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Santa Ana Bio in the Alameda ecosystem

Live from Dealroom

The Santa Ana Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States90.5%
🇬🇧 United Kingdom4.8%
🇨🇦 Canada4.8%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Santa Ana Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Santa Ana Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.